Company Launches Op-Ed Column on Critical Industry Topics

REDWOOD CITY, CA -- (Marketwire) -- 07/31/09 -- As a leader in the field of personalized medicine, Genomic Health Inc. (NASDAQ: GHDX), is now lending its perspective on important industry issues, via an online Op-Ed column titled "Our Perspective." The current article, "Our Perspective, Three Essential Components of Healthcare Reform," articulates the company's belief that personalized medicine has the power to improve the quality of care, reduce costs, and ultimately provide relief for each facet of the American healthcare system -- from the payor to the patient.

Genomic Health plans to use the column to weigh in on healthcare topics that are generating debate in Washington, on Wall Street and within the medical community. "We're looking forward to generating an Op-Ed type discussion," says Kim Popovits, President and CEO of Genomic Health. "Whether it's related to diagnostics, cancer treatment issues or a breakthrough technology -- we think it's important for Genomic Health to have a voice in these online conversations and encourage readers to visit our website to learn more about the promise of personalized medicine."

About Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched the Oncotype DX ® breast cancer test, which has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. In addition to the widely adopted Oncotype DX breast cancer test, Genomic Health is preparing to launch its Oncotype DX colon cancer test in early 2010.